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Olsen and colleagues show iImproved sample processing workflows enablefor 
rapidly obtaining comprehensive, deep analysis of human cellular and tissue 
proteomes. [AU: OK?] 
 
OPENING PARAGRAPH 
Technological advances in chromatography, mass spectrometry (MS), and data analysis 
have heralded a new era of proteomics that is characterised by increasingly detailed 
analyses of cellular proteomes from human cells and model organisms. In an article in 
this issue of Cell Systems, Olsen and colleagues describe how they have improved 
significantly upon “‘classic”’ workflows to allow rapid and impressively deep proteome 
coverage (~584,000 unique peptide sequences corresponding to 14,200 proteins 
identified) in a single human cancer cell line (HeLa) (Bekker-Jensen et al. 2017). The 
depth achieved in this study is indeed comparable with— - or even better -  than— the 
two recently reported “‘drafts”’ of the entire human proteome (Ahmad et al. 2014; 
Mollenhauer et al. 2014), which are based on data spanning diverse cell and tissue types. 
The deep coverage reported by Olsen and colleagues was enabled by the using use of 
multiple digestion enzymes and extensive peptide pre-fractionation, prior to LC-MS/MS.  
 A fast, high-throughput, and quantitative assay measuring the proteome of a 
single population of human cells in depth, either in tissue culture, or in tissues, would 
greatly accelerate biomedical research. For example, this couldan provide an objective 
and rigorous molecular definition of cell type identity (Hukelmann et al. 2016; Geiger et 
al. 2012; Ly et al. 2014). Importantly, it couldan potentially also enable comprehensive 
“‘snapshots”’ of proteome remodelling during diverse cellular processes, such as cell 
division (Ly et al. 2014) and differentiation (Van Hoof et al. n.d.). 
Making proteome analyses “‘comprehensive”’ poses major analytical challenges. 
One problem, for example, is that protein expression levels in human cells typically span 
a dynamic range of 7–-8 orders of magnitude. Unlike the situation for nucleic acid 
analysis, where the detection of low abundance species is facilitated by PCR 
amplification, there is no comparable amplification process available to aid detection of 
low abundance peptides. Another challenge is that searching reference databases, as 
required for peptide identification in most MS-based proteomics workflows, can be 
overwhelmed if the full diversity of potential peptide analyte species is included. For 
example, the human genome encodes at least 42,210 protein isoforms (SwissProt 
reviewed UniProt reference proteome), potentially giving rise to millions of distinct 
peptides upon protease digestion. The diversity of peptide analytes is further increased by 
both genetic variation and via post-translational modifications (PTMs)., Tthe latter 
hugely massively increasesing the size of the database  size needed to describe the full set 
of possible modified peptides. Furthermore, some PTMs are technically difficult to 
detect, either because the modifications are labile and easily lost during sample handling 
and mass spectrometry& MS, or because they are present in low abundance and/or low 
stoichiometry. 
Given these challenges, the depth of proteome coverage achieved by Olsen and 
colleagues, including detection of ~7,000 acetylation sites and ~10,000 phosphorylation 
sites, is a remarkable analytical achievement. To a large extent, this technical advance 
represents the effective combination of several methodological improvements previously 
described individually in the literature, including: i.e., extensive peptide pre-fractionation 
(46 fractions by high pH reverse phase)(Wang et al. 2011), use of short LC-gradients (30 
minutes) (Kelstrup et al. 2012; Hsieh et al. 2012), and protein digestion using multiple 
proteases (trypsin, LysC, chymotrypsin and GluC)(Swaney et al. 2010). In this study, 
~34–-35 hr of MS instrument time was sufficient to analyse by LC-MS/MS 46 fractions 
of fractionated tryptic peptides from a digest of total HeLa cell extract, resulting in 
identification of 0.17 million unique peptide sequences. Including the data from the three 
other protease digests analysed resulted in identification of another ~0.25 million 
peptides, resulting in a combined sum of 0.42 million unique peptide sequences. By 
several measures, including near-complete coverage of a “‘core”’ set of human protein 
complexes (CORUM), the authors argue that their analysis provides the, “essentially 
complete HeLa proteome.”.  
So, taking this claim at face value, how close are we to having a “‘complete 
proteome”’ of a human cell line? 
Answering this question involves agreeing first of all agreeing on a definition of 
what “‘complete”’ actually means (Mann et al. 2013). While a detailed discussion of such 
a definition is beyond the scope of this Preview, the study by Olsen and colleagues, along 
with other recent studies with high proteome depth, raise interesting points relevant to 
refining what is understood by “‘complete’.” For example, the combined number of 
peptides identified here, with six6 technical replicates using trypsin digestion (0.36 
million peptides), represents ~19% of the theoretical estimate of ~1.9 million peptides, 
i.e. the in silico tryptic digestion of the protein sequences encoded by the estimated 
>12,000 open reading frames annotated in the reference human genome. Furthermore, the 
average protein sequence coverage reported here (~52%), while potentially the highest 
achieved thus far for a single cell line, nonetheless means, by definition, that ~48% of 
protein sequences in this cell line were not detected. The authors also point out that their 
phosphorylation dataset, covering ~10,000 phosphorylation sites, while remarkably 
detailed considering that they did not use phosphopeptide enrichment, does not include a 
wide range of phosphopeptides previously identified in HeLa and other similar human 
cancer cell lines. Many other biologically important PTMs were not analysed in this 
study. In practice, therefore, the missing information places limitations on the resolution 
of the proteome with respect to isoform expression. 
This question of “‘proteome completeness”’, is reminiscent of a phenomenon in 
mathematics called the “‘coastline paradox,”’; i.e. in which, the measured value for the 
length of a convoluted coastline continually increases as the resolution of the 
measurement increases (Mandelbrot 1967). Extending the metaphor, just as the infinitely 
detailed and changing nature of a coastline’s contour necessitates drawing a practical 
limit on what is geographically meaningful, it will be important in future to evaluate, with 
respect to biological function, what depth of protein and PTM coverage will not only be 
practical to measure, but also required to mechanistically describe the phenotype of the 
cell or /tissue under study. Therefore, for the time being, we would respectfully suggest 
avoiding the potentially contentious term “‘complete”’ and focus instead on 
“‘comprehensive”’ proteome measurements.  
Semantics aside, Olsen and colleagues clearly present here a benchmark study 
that showcases the hugely impressive depth of coverage that can now be achieved by 
MS-based proteomics. Using a combination of extensive peptide pre-fractionation, short 
LC-gradients and protein digestion with multiple proteases, the authors obtained a 
comprehensive dataset profiling the HeLa cell proteome in a relatively short timeframe. 
The same workflow was also shown to be useful for obtaining comprehensive proteomic 
datasets on other cell lines and patient tissue samples. We look forward now to seeing 
this workflow applied in future studies on other cell types and used to take 
comprehensive “‘snapshots”’ of cellular and tissue proteomes in flux.  
 
Figure 1. A workflow for comprehensive proteome analysis using multiple proteases, 
extensive peptide fractionation, and short LC-MS/MS gradients. The cumulative depth 
obtained from HeLa is 14.2k proteins (12.2k protein-coding genes) using the above 
workflow and five additional technical repeats of trypsin.  The impressive analytical 
depth achieved by Olsen and colleagues (Bekker-Jensen et al. 2017) represents the 
effective combination of several methodological improvements previously described 
individually in the literature, but which, to our knowledge, have not been used together 
before. It should be possible for other groups to readily adopt the workflows. [AU: OK? 
Please ensure that all of the technical details in the figure are consistent with the 
text. For example, the figure states 11,300 proteins whereas the first paragraph 
states 14,200 proteins identified. Also, I suggest putting the number of proteins at 
the bottom of the workflow, instead of off to the side, because it is currently not 
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